Jupiter Neurosciences Starts Parkinson's Trial, Explores Strategic Options

Jupiter Neurosciences dosed the first patient in its Phase 2a RESET trial of JOTROL for Parkinson's disease. The company also retained Tungsten Advisors to explore potential asset monetization, partnerships, licensing, or other transactions.